A BIO-material for preventing post-surgery adhesion and process thereof

A biomaterial combining human serum albumin and Epigallocatechin gallate, crosslinked with Glutaraldehyde and Calcium Chloride, addresses the limitations of existing adhesion prevention methods by forming a stable, injectable, and sprayable hydrogel that effectively reduces post-surgery adhesions, enhancing clinical outcomes and reducing economic burdens.

WO2024241346A1PCT designated stage expired Publication Date: 2024-11-28NAT INST OF TECH ROURKELA
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
PCT/IN2024/050600
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-22
Filing Date
2024-05-22
Publication Date
2024-11-28

AI Technical Summary

Technical Problem

Current biomaterials for preventing post-surgery adhesions, such as hydrogel films and woven fabrics, have limitations including poor surface coverage, ease of dislodgment, and ineffectiveness on irregular surfaces, leading to modest success rates and significant economic and clinical burdens.

Method used

A biomaterial composed of a solution of human serum albumin and Epigallocatechin gallate, crosslinked with Glutaraldehyde and Calcium Chloride, forming a hydrogel that is injectable, sprayable, and provides effective tissue adhesion prevention by creating a stable barrier at the surgical site.

Benefits of technology

The biomaterial significantly reduces post-surgery adhesions, as demonstrated by reduced adhesion formation in animal models, with improved biocompatibility, mechanical robustness, and controlled degradation, offering a more effective solution than existing products.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure IN2024050600_28112024_PF_FP_ABST
    Figure IN2024050600_28112024_PF_FP_ABST
Patent Text Reader

Abstract

The present invention provides a process of preparing biomaterial for preventing post-surgery adhesion. The process includes preparing a first solution A by mixing a solution of protein selected from a group of albumin family and a solution of an antioxidant agent selected from a group of polyphenols in a predefined quantity. The process includes preparing a second solution B by mixing a first crosslinking agent selected from a group of aldehydes and a second crosslinking agent selected from a group of alkaline earth metal ions in a predefined quantity. The process further includes mixing the solution A and the solution B in a predefined quantity to prepare the said biomaterial.
Need to check novelty before this filing date? Find Prior Art

Description

A BIO-MATERIAL FOR PREVENTING POST-SURGERY ADHESION AND PROCESS THEREOFCROSS-REFERENCE

[0001] The present PCT application claims priority from Indian provisional patent application number 202231067042 dated May 22, 2023.FIELD OF THE INVENTION

[0002] The present invention relates to biomaterials for preventing the post-surgery adhesion and a process of preparing the same.BACKGROUND OF THE INVENTION

[0003] A tissue is traumatized during surgery, a serosanguinous exudate is released, forming a fibrinous bridge that lasts for many days and promotes cell proliferation. A permanent scar that links the two adjacent surfaces, known as an adhesion, is created if the exudate is not absorbed or lysed within this time frame, growing ingrown with fibroblasts.

[0004] These adhesions are very common and are encountered in around 95% of post- surgical cases, regardless of the surgery site.

[0005] More specifically, these post-surgical adhesions are a part of the natural healing process after surgeries.

[0006] The production of adhesions may be influenced by a variety of causes, including mechanical damage, chemical agents, blood, and serosa drying, ischemia, infection, and foreign material. Congenital defects and intraabdominal inflammatory disorders are additional reasons.

[0007] The adhesions are responsible for persistent complications after surgery, including chronic pain, organ dysfunction, infertility, and the need for a “redo surgery” to segregate the adhered tissue (adhesiolysis).

[0008] Adhesions cause increased medical costs in addition to pain and physical problems. Additional surgeries to remove or separate adhesions, doctor visits, painkillers, and compensation for lost work time are all expenses.

[0009] The treatment of post-surgical adhesions has a substantial economic burden. It accounts for USD 2.5 billion annually in the United States (US) alone, in addition to the nearly one million extra days of inpatient care every year.

[0010] Although the pathophysiological mechanism is still unknown, a major common pathway has been proposed in which peritoneal fibrinolysis plays a significant role.

[0011] Further, if a patient underwent a subsequent procedure at the same surgical site, those adhesions may complicate the procedure. Before starting a new procedure, surgeons must spend a significant amount of time removing the adhesions.

[0012] Additionally, this could lengthen the patient's recuperation period and raise the expense and danger of the operation.

[0013] Several anti-inflammatory and anticoagulant medications, such as dexamethasone, aspirin, and heparin, have been studied to prevent post-surgical adhesions.

[0014] However, none of them have been able to produce the desired outcomes.

[0015] Another method is introduced in which a physical barrier such as hydrogels or polymeric films is placed between potential adhesion-forming tissue surfaces.

[0016] Until now, a wide range of materials has been used as barriers to prevent post- surgical adhesions (PSA). These include hydrogel films made from polysaccharides or synthetic polymers based on physically separating the tissue to prevent adhesion.

[0017] Currently, commercially available products include films (Seprafilm, Baxter) and woven fabric (Interceed, Ethicon), which offer some degree of protection against PSAs. These are composed of natural polymers like hyaluronic acid (HA) and carboxymethylcellulose (CMC).

[0018] Although they offer protection against PSAs, they still entail drawbacks like poor surface coverage, dislodging easily during tissue movement, and are ineffective in irregular or folded surfaces such as the small intestines.

[0019] Further, these anti-adhesive barriers still have modest success rates.

[0020] To overcome these drawbacks, researchers have been looking for sprayable and injectable alternatives that may easily cover irregular surfaces, have good biocompatibility and biodegradability and offer better attachment to the surgery site.

[0021] Therefore, there is a need for a more effective composition or biomaterial that may drastically lower post- surgery adhesions.

[0022] In nutshell, a composition is required which may overcome above discussed drawbacks and provides an effective way of preventing post-surgery adhesions.SUMMARY OF THE INVENTION

[0023] The present invention discloses a process of preparing biomaterial for preventing post-surgery adhesion.

[0024] In an embodiment of the present invention, the biomaterial takes the form of one of from hydrogels, films, woven tissues, or blends, nonwoven tissues.

[0025] In one embodiment of the present invention, the process includes preparing a first solution A by mixing a solution of protein selected from a group of albumin family and a solution of an antioxidant agent selected from a group of polyphenols in a predefined quantity.

[0026] In the embodiment of the present invention, the said protein includes but not limited to Human serum albumin which is maintained at pH of about 8.5.

[0027] In one embodiment of the present invention, the said antioxidant agent includes but not limited to Epigallocatechin gallate (EGCG), also known as epigallocatechin-3 -gallate which is maintained at a pH of about 8.

[0028] In one embodiment of the present invention, the process further includes preparing a second solution B by mixing a first crosslinking agent selected from a group of aldehydes and a second crosslinking agent selected from a group of alkaline earth metal ions in a predefined quantity.

[0029] In one embodiment of the present invention, the said first crosslinking agent includes but not limited to Glutaraldehyde which acts as primary crosslinker.

[0030] In one embodiment of the present invention, the said second crosslinking agent includes but not limited to Calcium Chloride (CaC12) adapted to provide dual-crosslinking to said biomaterial.

[0031] In one embodiment of the present invention, the process further includes mixing the solution A and the solution B in a predefined quantity to prepare the said biomaterial.

[0032] In the embodiment of the present invention, the said solution A and the said solution B are mixed in equal quantity.

[0033] This together with the other aspects of the present invention along with the various features of novelty that characterized the present disclosure is pointed out with particularity. For better understanding of the present disclosure, its operating advantages, and the specified objective attained by its uses, reference should be made to the accompanying descriptive matter in which there are illustrated exemplary embodiments of the present invention.BRIEF DESCRIPTION OF THE DRAWINGS

[0034] The advantages and features of the present invention will become better understood with reference to the following detailed description taken in conjunction with the accompanying drawings, in which:

[0035] Fig. 1 illustrates a flowchart representing a process of preparing a bio-material for preventing post-surgery adhesion, according to various embodiments of the present invention.

[0036] Fig. 2 (a) and Fig. 2 (b) illustrates gelation time(in seconds) at different concentrations for ratio 6:4 and 5:5 respectively.

[0037] Fig. 3 shows the burst pressure results for 5:5 ratio of the hydrogel.

[0038] Fig. 4 shows a graph depicting the swelling and degradation of the hydrogels of different concentrations for the ratio of 5:5.

[0039] Fig. 5 shows a graph depicting MTT results for 5:5 hydrogel for varying concentrations of EGCG and the crosslinker.

[0040] Fig. 6 illustrates shows the components of the hydrogels being ejected from a dual mixing syringe. This shows the injectability of the formulation.

[0041] Fig. 7 shows the formed hydrogel after the components were sprayed into the petridish.

[0042] Fig. 8 illustrates shows an image of the invert tube method utilized for the estimation of the gelation time of the hydrogels.

[0043] Fig. 9 (a) shows the components of the hydrogel being sprayed into a petri dish, indicating the sprayability of the formulation.

[0044] Fig. 9 (b) shows the hydrogel formed after the components are injected out from a dual mixing syringe.

[0045] Fig. 10 on left depicts the hydrogel sample and the one on right is the control sample.

[0046] Fig. 11 described the adhesion formation in SD rat models. Fig (A, B, C and D) showed untreated models (control) where adhesion was formed. And fig (E, F, G, H and I) explained the treated animals with hydrogel where adhesion was not formed.

[0047] Like numerals denote like elements throughout the figures.DESCRIPTION OF THE INVENTION

[0048] The exemplary embodiments described herein detail for illustrative purposes are subjected to many variations. It should be emphasized, however, that the present invention is not limited to as disclosed. It is understood that various omissions and substitutions of equivalents are contemplated as circumstances may suggest or render expedient, but these are intended to cover the application or implementation without departing from the spirit or scope of the present invention.

[0049] Specifically, the following terms have the meanings indicated below.

[0050] The terms “a” and “an” herein do not denote a limitation of quantity, but rather denote the presence of at least one of the referenced items.

[0051] The terms “having”, “comprising”, “including”, and variations thereof signify the presence of a component.

[0052] The present invention relates to the technology for preventing post-surgery adhesion. More specifically, the present invention discloses a Biomaterial for preventing post-surgery adhesion and process of preparing the said biomaterial.

[0053] The inventive aspects of the invention along with various components and engineering involved will now be explained with reference to Fig. 1 herein.

[0054] In one embodiment of the present invention, the process for preparing the biomaterial used for prevention of the post -surgery adhesion.

[0055] In an embodiment of the present invention, the biomaterial takes the form of one of from hydrogels, films, woven tissues, or blends, nonwoven tissues.

[0056] In an exemplary embodiment of the present invention, the biomaterial is taken the form of in-situ hydrogel.

[0057] The term “In situ” denotes at a local surgical site, especially within or in contact with living organisms, tissue, organs, or the body.

[0058] Referring to Fig. 1, a flowchart representing the process (50) for preparing the biomaterial for prevention of the post-surgery adhesion.

[0059] At step (10), the process (50) involves preparing solution A by mixing protein which is selected from a group of albumin family and an antioxidant agent selected form a group of polyphenols in a predefined quantity (refer Fig.l).

[0060] Natural proteins have been widely used to form hydrogels owing to their excellent biocompatibility and biodegradability. Several protein-based hydrogels have already been reported, which include fibrous proteins (e.g., collagen, keratin, elastin, and silk fibroin) and also globular proteins (e.g., lactoglobulin, serum albumin, casein, and ovalbumin).

[0061] In an embodiment of the present invention, Human serum albumin (HSA) is used as the protein. However, it should be understood that the use of the Human serum albumin (HSA) for preparation of the biomaterial should not be construed as a limitation of the present invention.

[0062] In the embodiment of the present invention, the Human serum albumin (HAS) solution is maintained with a pH of about 8.5.

[0063] Human serum albumin (HAS) is chosen for anti-adhesive hydrogel preparation given its negatively charged surface, non -immunogenicity, and it being devoid of any Arginyl-glycyl-aspartic acid (RGD) sequences, which play a significant role in cell adhesion.

[0064] In another embodiment of the present invention, the other proteins form the group of the albumin family may also be used for the preparation of the said biomaterial.

[0065] In an exemplary embodiment of the present invention, the Human Normal Albumin 20%) is acquired from Reliance Life sciences.

[0066] In one embodiment of the present invention, the said antioxidant is Epigallocatechin gallate (EGCG), also known as epigallocatechin-3-gallate. However, it should be understood that the use of Epigallocatechin gallate (EGCG) as the antioxidant agent should not be construed as a limitation of the present invention.

[0067] In the embodiment of the present invention, the said Epigallocatechin gallate (EGCG) solution of varying concentration is mixed with a solution of the Human serum albumin (HSA).

[0068] In the embodiment of the present invention, the said Epigallocatechin gallate (EGCG) solution is maintained at a pH of about 8.

[0069] In an exemplary embodiment of the present invention, EGCG (Epigallocatechin gallate) is obtained from Sigma-Aldrich.

[0070] In various embodiment of the present invention, the HSA solution is mixed with the Epigallocatechin gallate (EGCG) solution to prepare solution A.

[0071] Again, referring to Fig. 1, at step (12), the process (50) involves preparing solution B by mixing a first crosslinking agent selected from a group of aldehydes and a second crosslinking agent selected from a group of alkaline earth metals ions.

[0072] The “Crosslinking agents” are used tie together carbon atoms from different chains of the polymer, transforming what were once viscous linear segments into an insoluble gel network that no longer melts or flows like a typical thermoplastic.

[0073] In one embodiment of the present invention, the first crosslinking agent is Glutaraldehyde, as HSA contains abundant amino acids. However, it should be understood that the use of Glutaraldehyde as the primary crosslinking agent should not be construed as a limitation of the present invention.

[0074] In another embodiment of the present invention, the first crosslinking agent with the properties same as Glutaraldehyde may also be used as the primary crosslinking agent.

[0075] In the embodiment of the present invention, Glutaraldehyde being an aminereactive crosslinker has been explored in the past to form protein-based hydrogels due to its behavior in aqueous solution.

[0076] In an exemplary embodiment of the present invention, Glutaraldehyde, Grade II, 25% in H2O is obtained from Sigma- Aldrich.

[0077] Due to cytotoxicity nature of Glutaraldehyde, it is customary to minimize the concentration of glutaraldehyde to form hydrogels.

[0078] However, at lower concentrations, the hydrogels formed are weak and have delayed gelation times.

[0079] In order to produce robust hydrogels with fast gelation time, calcium ions such as (CaCh) are used as the second crosslinking agent to provide dual-crosslinking, and thereby help to reduce the concentration of Glutaraldehyde, which leads to reduction of cytotoxicity.

[0080] In the embodiment of the present invention, the calcium chloride concentration is fixed at about 0.08 Molarity (M) for preparing hydrogels.

[0081] In an exemplary embodiment of the present invention, Calcium chloride anhydrous is acquired from Hi-media, 20 mM Potassium Phosphate Buffer Saline (PBS) prepared in the laboratory.

[0082] In various embodiments of the present invention, the Glutaraldehyde of varying concentrations is mixed with the calcium chloride concentration to prepare solution B .

[0083] Coming back to Fig.l, at step (14), the process (50) involves mixing solution A with solution B in a predefined quantity to prepare biomaterial (hydrogel) for preventing post-surgery adhesion.

[0084] In the embodiment of the present invention, the examples showing the preparation of the hydrogels, its characteristic properties, the in-vitro and in-vivo data showing use as a barrier for tissue adhesion are described in the below paragraphs. The following examples are illustrative of the present invention, however, it will be understood that the invention is not limited to the specific details set forth in the examples.

[0085] Example l.~

[0086] The process of preparing the exemplary Hydrogel started by mixing two different solutions, namely, a solution A and a solution B. The Solution A contained a solution of protein selected from a group of albumin family and a solution of an antioxidant agent selected from a group of polyphenols. For the exemplary hydrogel, Human serum albumin (HAS) was selected as a protein from the albumin family and Epigallocatechin gallate (EGCG) was selected as an antioxidant agent.

[0087] The Solution B contained a first crosslinking agent selected from a group of aldehydes and a second crosslinking agent selected from a group of alkaline earth metal ions. For the exemplary hydrogel, glutaraldehyde was selected as first crosslinking agent and calcium chloride with a fixed concentration at 0.04 M was selected as the second crosslinking agent.

[0088] The HSA and EGCG of varying concentrations were mixed in equal volumes. The EGCG solution of varying concentrations was prepared, and the pH of the solution was adjusted to 8 before mixing it with the HSA solution. The pH of HSA solution was maintained at 8.5. The equal volumes of solution A and B were mixed to form the hydrogel.

[0089] In the embodiment of the present invention, the exemplary illustrations of the prepared samples of hydrogels with varying concentrations of materials used in the present invention are shown in Table- 1 as follows:Table-1

[0090] Example 2:Confocal / anti-adhesive study:

[0091] A. Gelation time study:

[0092] The gelation time of the samples was recorded from the point of mixing to when the gels stopped flowing inside the MCTs. It was analyzed that the gelation time was affected by the EGCG concentration as well as the glutaraldehyde concentration. The gelation times decreased with the increasing concentration of both EGCG and glutaraldehyde.

[0093] The results of the gelation time study are provided in Fig. 2 (a) and Fig. 2 (b). The data in figures 2(a) and (b) depicts the gelation time(in seconds) at different concentrations for ratio 6:4 and 5:5 respectively. The results shown in the graph indicate that the gelation time of the hydrogel is an inverse function of the concentration of the EGCG and the crosslinker concentration. An increase in the concentration of EGCG and the crosslinker decreases the gelation time of the hydrogel.

[0094] B. Swelling and degradation study:

[0095] The samples for the study were prepared in MCTs, and the weight of the gels was kept the same at around 400+20 mg. The samples were then transferred into a 24-well plate and dipped in 20 mM PBS solution and kept at room temperature. The gels were weight by removing from PBS and wiping the excess liquid by tissue paper after 10 minintervals for the first hour and then hourly until a saturation point was reached. The swelling percentage was calculated using the formula given below: 100Where Wf and Wi are the final and initial weights of the hydrogel respectively.

[0096] For the degradation study, the gels were kept in the same PBS solution at room temperature and the point after the saturation point was taken as the starting of the degradation. The gels were removed from the PBS solution after every 2 days, wiped with tissue paper, and readings were taken. The PBS was changed whenever the weights of the samples were taken and the degradation time was estimated using the following formula. The point where the readings tended to zero was considered as the final degradation time of the given sample.Wf Relative Mass(%) = - x 100WiWhere Wf and Wi are the final and initial weights of the hydrogel respectively.

[0097] The results of the swelling and degradation study are provided in Fig. 4. The hydrogels of different concentrations for the ratio of 5:5 were shown. The results from this graph indicate that all the hydrogels show very less swelling behavior and the samples with low concentration of crosslinker are more prone to degradation and vice versa.

[0098] Biodegradation: Biodegradation of the prepared hydrogels was estimated by immersing the gels in 0.5 mg mL-1 of lysosome solution prepared in PBS and incubating the samples at 37 degrees Celsius. The initial weights of the hydrogels were noted before immersing them in the solution and then the subsequent readings were taken after every 10 minutes for the first hour and then every two hours until complete degradation the lysosome solution of the samples was changed after every 48 hours to avoid contamination the relative mass of the hydrogel was calculated by the following equation:Wf Relative Mass(%) = —— X 100 WiWhere Wf and Wi denotes the final and initial weights of the hydrogels respectively.

[0099] C. MTT assay: MTT assay / cell viability assay: The cytocompatibility of the hydrogels was assessed by MTT((3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide)) assay with an already established protocol (1). The hydrogels of different compositions were prepared in a sterile environment in MCTs, and small discs of 0.4g weight were cut from each sample. The cut samples were then subjected to UV radiation for 1 hour to assure sterilization. These were then transferred to a 24-well plate and were dipped in 2ml complete Dulbecco Modified Eagle Media (DMEM) each and incubated for 24 hrs in a CO2 incubator at 37°C. Simultaneously, triplicate wells containing 104L929 fibroblast cells per well were seeded in a 96-well plate and incubated for 24 hrs. After the incubation period, the media from the 96-well plate was aspirated from each well, and 100 pl of extract from each sample in triplicates was seeded per well 3 wells were seeded with 100 pl complete media again and served as control. The 96-well plate was incubated further for 24 hrs. After the incubation, the extract and the media from each well were removed, and 50 pl of 1 mg / ml MTT reagent was seeded in each well. MTT being lightsensitive, this whole step was completed in the dark. The plate was further incubated for 4 hrs in the CO2 incubator. After incubation, the 96-well plate was removed, the MTT reagent was aspirated from each well, and 100 pl solubilizing agent was added to each well, and the plate was shaken for 20 minutes. Finally, the plate was transferred to a microplate reader, and absorbance was taken at 595 nm. The OD values from the samples were compared against the control and then plotted, and cell viability was calculated.

[0100] The results of the cell viability study are provided in Fig. 5. The MTT results for 5:5 hydrogel for varying concentrations of EGCG and the crosslinker. The results indicate that the cell viability of the samples is inversely related to the crosslinker and the EGCG concentration of the samples.

[0101] D. Elastic Modulus: The elastic modulus of the hydrogels was assessed by taking the stress strain curve obtained from the compression test data by calculating the slope of the elastic region at 5% Strain rate.

[0102] E. Tissue adhesion: Tissue adhesion of the hydrogels was estimated by pouring the mixture of the hydrogel components directly onto the rectangular cut clean porcine skin and covering about two-third of one rectangular strips and placing another strip on top of it. These porcine strips were kept under constant weight until the hydrogel was fully gelled. The strips were then placed in a UTM machine where the tissue adhesion of thegels was measured by stretching the porcine skin strips from the sides. Require the dimensions of the skin strips.

[0103] F. Burst Pressure: The burst pressure test was conducted in accordance with ASTM F 2392-04 Standard for burst pressure strength of surgical sealants (2). Clean porcine skin was taken and holes of 3 mm standard size were made in the middle of the skin piece. The mixture of the hydrogel components was poured onto the hole and left to gel for some time. The samples were then subjected to varying fluid pressure, placed in a setup to measure the pressure tolerance of the fissure having the hydrogel.

[0104] The results of the burst pressure study are provided in Fig. 3. The burst pressure results for 5:5 ratio of the hydrogel is shown in the figure. The results from the graph indicate that with increase in the crosslinker concentration the burst pressure value of the hydrogels increases significantly.

[0105] G. Confocal Microscopy

[0106] The confocal microscopy of the samples revealed that the prepared hydrogel samples show almost no adhesion to the seeded L929 Fibroblasts. This can be attributed to the fact that the components of the hydrogel are devoid of RGD sequences that help in cell adhesion via integrin binding. Following images from the hydrogel and the control sample confirm the anti-cell adhesive nature of the prepared hydrogels.

[0107] Fig. 10 on the left side shows the hydrogel sample and the one on the right is the control sample. The samples revealed that the prepared hydrogel samples show almost no adhesion to the seeded L929 Fibroblasts.

[0108] Example 3: Spray ability & Injectability Assessment:

[0109] The findings of research into the injectability and spray ability of the developed hydrogels are shown in Figure 6-9. To assess the injectability of the Alburel / EGCG hydrogel, the solution Alburel / EGCG with dual crosslinker was loaded into two distinct syringes in a twin- syringe applicator (Figure 9. A). The two precursor solutions were extruded in situ at room temperature (25°C) through a "Y" -shaped connector and a static mixture after the plungers were pressed down. To evaluate the hydrogels' spray ability, equal amounts of solutions A and B were put into bottles that could be sprayed. Hydrogelswere formed at room temperature (25 °C) by extruding the solutions via a "Y" shape connection and a static mixture.

[0110] Example 4: In-Vivo Study:

[0111] The disclosure and examples depict that the adhesion-preventing material can be used as a barrier for tissue adhesions. Furthermore, the present invention relates to a Alburel / EGCG and a method for making the hydrogel. This disclosure of Alburel / EGCG structure can be used for as a preventive hydrogel between tissues and internal organs, especially for articles that also maintain its shape, in the body for certain period of time before being absorbed, including adhesion-preventing product, base sheet for fibrin sealeant, resorbable suture-reinforcing material, artificial dura, and resorbable suture. The results of current research described the the adhesion preventive effects in animal models. The number of animals tested were 20 and the results did perform well to prevent adhesions in either digit (< 10%). The results of the present invention showed adhesion preventive effects in adhesion forming animals.

[0112] A. Peritoneal Adhesions:

[0113] Twenty Sprague-Dawley rats were used as model animals for the preventive adhesion studies. All rats were treated humanely throughout the experimental period. These animals were assigned to two experimental groups:I. no treatment (n =4);II. covering the injured areas with 2 ml Alburel / EGCG hydrogel membrane (n=16).

[0114] B. Design of animal studies:

[0115] Sprague -Dawley rats weighing between 300 gm and 350 gm were used for the study. Rats were anesthetized by ketamine / xylazine (60-100 mg / kg ketamine, 8-12 mg / kg xylazine) administered IP. A single dose of either atropine (0.04mg / kg IM or SC) or glycopyrrolate (0.01-0.02mg / kg IM or SC) was administered to decrease airway secretions and lubrication was placed in the eyes. Additionally, all rats received a single dose of buprenorphine (0.01-0.05mg / kg SC) or butorphanol (2mg / kg SC) immediately pre-op for increased analgesia. The ventral abdomen was shaved and bupivacaine (0.03 -0.05ml of 0.125% solution) was injected subcutaneously along the predicted incision site as a local anesthetic. The shaved area was then scrubbed with three alternating applications ofsurgical scrub solution and isopropyl alcohol. The rat was then placed in dorsal recumbency and draped on a heating pad. Using aseptic surgery techniques (no touch technique), a 6-8cm incision was made through the skin on the ventral abdomen, exposing the linea alba. No more than three peritoneal ischemic buttons were created in the lateral wall on each side (left and right, maximum of 6), spread approximately 2-3 cm apart. The buttons were created by first grasping ~3-6 mm of the lining of the peritoneal wall (parietal peritoneum) with locking forceps. A ligature was then placed at the base of the grasped tissue (between the tips of the forceps and the body wall), tightened and tied, and the forceps released. This created a focal area of ischemic necrosis several millimeters in diameter, which in turn promoted adhesion formation. Adhesion prevention gels (alburel / EGCG) (~lxlcm) was then spread over the buttons. The body wall was closed with suture. Skin was then closed either with simple interrupted sutures or wound clips. If animals become light at any point during the surgery they were attached to an isoflurane anesthetic system for the remainder of the procedure. Rats can be reversed with yohimbine (2mg / kg SC) postop, if desired. All rats received 3cc of normal saline SC immediately after surgery and an additional dose of buprenorphine (0.01-0.05mg / kg SC) or butorphanol (2mg / kg SC) within 12 hrs of surgery. However, animals that displayed evidence of continuing pain received buprenorphine 2-3 times a day or butorphanol 4-6 times a day for 2-3 days post-operatively (or as directed by LAS staff). Any animal that showed evidence of infection was placed on baytril (5-15mg / kg IP BID) for no less than three days.

[0116] C. Preclinical Studies:

[0117] The findings of the study demonstrated the value of the disclosed products in reducing post-surgical adhesions and demonstrate how those goods perform better than previously known products. To reduce a patient's burden as much as possible, it is ideal for a medical material (such as an adhesion-preventing material) that be inserted into the body for a specific amount of time to dissolve and be absorbed by the body as soon as it is no longer needed (that is, when adhesions of living tissues are not possible, for example). Therefore, controlling a dissolution half-life alone is insufficient to release the patient of this burden. It is desirable that a medical material has controllable periods of functioning and dissolving, as well as dissolution half-life.

[0118] D. Prevention of peritoneal adhesions:

[0119] In SD rats, adhesions were generated by removing some of the surrounding peritoneal wall and abrading the cecum. Adhesions between the damaged cecum and peritoneal wall were observed in the untreated rats at 4 weeks (Fig. 11: A, B, C and D). Nevertheless, none of the rats given the hydrogel according to Alburel / EGCG showed any signs of adhesions. As seen in Figure 11, this Alburel / EGCG hydrogel must create a barrier between the wounded cecum and surrounding tissues by forming a protective membrane around it. Adhesions between the peritoneal wall and cecum persisted after four weeks of treatment in the untreated SD rats (control) (Fig. 1).

[0120] Once more, rats treated with developed hydrogel did not exhibit any adhesions. It was evident that the wounded cecum and peritoneal wall were distinct from one another (Fig. 11. E, F, G, H, and I). Nevertheless, the area of adhesions was significantly decreased in rats given this hydrogel treatment, even though some fibroblasts remained over the wounded cecum (Fig. 11. I). Rats that received no treatment had more adhesions after four weeks. After 4 weeks, the damaged cecum had fully recovered in comparison to the untreated rats.

[0121] E. Gross Observation and Adhesion Score Evaluation:

[0122] The SD rats were humanely euthanized with CO2 asphyxiation and cervical dislocation, following Animal Welfare Act guidelines, at POD 30. To assess the outcome of adhesion formation and wounded tissue healing, the sutured line was reopened following skin dissection to reveal the injured or repaired region. Using a double-blind scoring procedure, the rat's level of adhesions was assessed using the conventional adhesion scoring system: GradeO: no adhesion; Gradel: one thin filmy adhesion that needs to be divided gently using blunt dissection; Grade2: many thin adhesions; Grade 3: one thick adhesion with a focal point; Grade 4: one thick adhesion with plantar attachment or more than one thick adhesion with focal points; Control: very thick vascularized adhesions or more than one planter adhesions. (Table 2, Table 3 and Figurel 1).

[0123] Adhesion score: Severity of most significant adhesionsGrade-0= No adhesion;Grade-1= 25% thin and filmy adhesion;Grade-2= 50% more than one thin adhesion;Grade-3= 75% thick adhesion with the focal point;Grade-4= 90% traumatized tissues, thick adhesion, and planar attachment;Control traumatized tissue adhesions were formed between internal organs and tissues.

[0124] RESULTS:

[0125] It is evident that the use of the said Alburel / EGCG material of the invention as a barrier (impermeable to inflammatory cells ) between an injured, inside surface ( peritoneal wall ) and the adjacent organs, reduces the in formation of adhesions, as compared to 100% of adhesions in the control group. Table.2 stated the percentage of adhesion area formed in the SD rat model. The application of this novel hydrogel significantly reduces adhesion formation. Sample no. 4 showed the best efficacy, resulting in only 0.07 % adhesion formation, whereas sample no. 1 was the least effective, which led to the adhesion formation of 1.27% of the total area. In both the crosslinker concentrations used, an increase in EGCG led to a decrease in adhesion percentage.Note. It has to be kept in mind though that the number of animals tested were limited and some animals did not form restrictive adhesions in either digit ( close to 50%).

[0126] TABLE 2: Showed the % of adhesions in treated animal model comparing with untreated animals:

[0127] Inference:

[0128] It is clear that using the aforementioned Alburel / EGCG material of the invention as an impermeable barrier to inflammatory cells between a damaged internal surface (peritoneal wall) and the surrounding organs decreases the production of adhesions, as opposed to the control group, which had 100% of adhesions.

[0129] The table-2 data depicts the percentage of adhesion area formed in the SD rat model. The application of this novel hydrogel significantly reduces adhesion formation. Sample no. 4 showed the best efficacy, resulting in only 0.07 % adhesion formation, whereas sample no. 1 was the least effective, which led to the adhesion formation of 1.27% of the total area. In both the crosslinker concentrations used, an increase in EGCG led to a decrease in adhesion percentage.

[0130] TABLE 3: Explained the severity adhesion in treated SD rat model:Four grades of adhesion severity was observed in SD rat model from 0-4, 0 being least severe to 4 being the most.

[0131] Inference:

[0132] It is evident that the use of these slowly biocompatible biomaterials as an impermeable barrier to inflammatory cells between two adjacent surfaces reduces the formation of adhesions, as compared to 100% of adhesion observed in the control group described. Adherences with a score of >3 were considered significant. In the positive control group where the adhesion were formed between peritoneal wall and internal organs in 4 SD rat models out of 4 (100%) presented adherence formation with a score of >3; whereas, where there was a significant reduction in the incidence of adhesion formation between the peritoneal wall and internal organs when when utilizing the product of the invention, as shown in table 2 and 3.

[0133] Advantageous effects of the present invention

[0134] In one embodiment of the present invention, the Hydrogel prepared from the process described in the present invention is albumin / EGCG-based, which is highly biocompatible nature.

[0135] Further, the hydrogel of the present invention is injectable and sprayable, so it may be used for laparoscopic surgeries.

[0136] Furthermore, dual-crosslinking strategy is adapted in the present invention to reduce the crosslinker-induced cytotoxicity, at the same time forming hydrogels that are mechanically robust that have good tissue adhesion and are tissue complaint.

[0137] In an exemplary embodiment of the present invention, tissue adhesive strength of hydrogel of the present invention is around 100 kPa.

[0138] In addition, the hydrogel of the present invention gets prepared with within short duration (about 1-4 minutes).

[0139] Moreover, the hydrogel is stable in aqueous condition up to 28 days, which is optimum for anti-adhesion applications.

[0140] In nutshell, the process of the present invention, overcome above discussed drawbacks and provides an easy-to-use biomaterial for preventing post-surgery adhesion.

[0141] The foregoing descriptions of specific embodiments of the present invention have been presented for purposes of description. They are not intended to be exhaustive or to limit the present invention to the precise forms disclosed, and obviously many modifications and variations are possible in light of the above teaching.

[0142] Further, the embodiments were chosen and described in order to best explain the principles of the present invention and its practical application, and thereby enable others skilled in the art to best utilize the present invention and various embodiments with various modifications as are suited to the particular use contemplated.

[0143] It is understood that various omissions and substitutions of equivalents are contemplated as circumstances may suggest or render expedient, but such omissions and substitutions are intended to cover the application or implementation without departing from the spirit or scope of the present invention.

Claims

CLAIMS:

1. A process (50) of preparing biomaterial for preventing post-surgery adhesion, the process comprising: preparing a first solution A, by mixing a solution of protein selected from a group of albumin family and a solution of an antioxidant agent selected from a group of polyphenols in a predefined quantity; preparing a second solution B, by mixing a first crosslinking agent selected from a group of aldehydes and a second crosslinking agent selected from a group of alkaline earth metal ions, in a predefined quantity; mixing the solution A and the solution B in a predefined quantity to prepare the said biomaterial.

2. The process (50) as claimed in claim 1, wherein the said biomaterial takes the form of one of from hydrogels, films, woven tissues, or blends, nonwoven tissues.

3. The process (50) as claimed in claim 1, wherein the said solution A and the said solution B are mixed in equal volume, in 1 : 1 ratio.

4. The process (50) as claimed in claim 1, wherein the said protein includes but not limited to Human serum albumin (HAS) which is maintained at pH of about 8.5.

5. The process (50) as claimed in claim 1, wherein the said antioxidant agent includes but not limited to Epigallocatechin gallate (EGCG), also known as Epigallocatechin-3- gallate.

6. The process (50) as claimed in claim 1, wherein the said antioxidant agent, EGCG is maintained at pH of about 8.

7. The process (50) as claimed in claim 1, wherein the said first crosslinking agent includes but not limited to Glutaraldehyde which acts as primary crosslinker.

8. The process (50) as claimed in claim 1, wherein the said second crosslinking agent includes but not limited to Calcium Chloride (CaCl2) adapted to provide dual-crosslinking to said biomaterial.

9. The process (50) as claimed in claim 1, wherein the concentration of the Calcium Chloride (CaCl2) is 0.04M.

10. A biomaterial for preventing post-surgery adhesion, wherein the said biomaterial is prepared by the process claimed in claims 1 to 9.

11. Use of the biomaterial prepared by the process claimed in claims 1 to 9, for preventing post-surgery adhesion.

12. A method of preventing post-surgery adhesion using the biomaterial as prepared by the process claimed in claims 1 to 9.

13. A biomaterial for preventing post-surgery adhesion, wherein the said biomaterial is prepared by a process comprising of: preparing a first solution A, by mixing a solution of protein selected from a group of albumin family and a solution of an antioxidant agent selected from a group of polyphenols in a predefined quantity; preparing a second solution B, by mixing a first crosslinking agent selected from a group of aldehydes and a second crosslinking agent selected from a group of alkaline earth metal ions, in a predefined quantity; mixing the solution A and the solution B in a predefined quantity to prepare the said biomaterial.

14. The biomaterial as claimed in claim 13, wherein the preparation of said biomaterial the first protein includes but not limited to Human serum albumin (HAS), wherein the said antioxidant agent includes but not limited to Epigallocatechin gallate (EGCG), also known as Epigallocatechin-3 -gallate, wherein the said first crosslinking agent includes but not limited to Glutaraldehyde which acts as primary crosslinker. wherein the said second crosslinking agent includes but not limited to Calcium Chloride (CaCh) adapted to provide dual-crosslinking to said biomaterial.

15. The biomaterial as claimed in claim 13, wherein preparation process the said first protein is maintained at pH of about 8.5, and the antioxidant agent is maintained at a pH of about 8.0.

Citation Information

Patent Citations

  • PROCESS FOR OBTAINING CROSSLINKED PVA HYDROGELS WITH GLUTARALDEHYDE ASSOCIATED WITH A FUNCTIONALIZED AMINO TANNIN DERIVATIVE FOR BIOMEDICAL APPLICATIONS

    BR102019022970A2

  • Injectable hydrogel for prevention of post-surgical adhesions

    IN202131036067A

  • Semiconductor device

    KR102337708B1